文章：

EGFR、HER2及c-MET过表达对壶腹腺癌手术患者的预后意义

Prognostic Significance of EGFR, HER2, and c-Met Overexpression in Surgically Treated Patients with Adenocarcinoma of the Ampulla of Vater

原文发布日期：3 August 2024

DOI: 10.3390/cancers16152756

类型: Article

开放获取: 是

英文摘要：

Adenocarcinoma of the ampulla of Vater (AAC) is a rare malignancy with heterogeneous tumors arising from various histologic subtypes, necessitating new therapeutic strategies. This study examines epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and c-Met expression in AAC, given their potential as druggable targets. Among 87 patients who underwent curative resection, EGFR overexpression was found in 87.4%, HER2 in 11.5%, and c-Met in 50%. EGFR overexpression was more common in the pancreatobiliary subtype (p= 0.018) and associated with a higher histologic grade (p= 0.008). HER2 did not correlate with clinicopathological features, while c-Met was more common in node-negative groups (p= 0.004) and often co-expressed with EGFR (p= 0.049). EGFR-positive patients had worse disease-free (HR = 2.89; 95% CI, 1.35–6.20;p= 0.061) and overall survival (HR = 6.89; 95% CI, 2.94–16.2;p= 0.026) than EGFR-negative patients. HER2-positive AAC showed a trend towards shorter survival, although not statistically significant, and c-Met had no impact on survival outcomes. In the context of systemic disease, survival outcomes did not vary according to EGFR, HER2, and c-Met expression, but the HER2-positive group showed a trend towards inferior progression-free survival (HR = 1.90; 95% CI, 0.56–6.41;p= 0.166). This study underscores the potential of EGFR, HER2, and c-Met as targets for personalized therapy in AAC, warranting further research to evaluate targeted treatments.

摘要翻译： 

壶腹腺癌是一种罕见的恶性肿瘤，其肿瘤异质性源于不同的组织学亚型，因此需要新的治疗策略。鉴于表皮生长因子受体、人表皮生长因子受体2和c-Met作为潜在药物靶点的可能性，本研究探讨了它们在壶腹腺癌中的表达情况。在87例接受根治性切除术的患者中，表皮生长因子受体过表达率为87.4%，人表皮生长因子受体2为11.5%，c-Met为50%。表皮生长因子受体过表达在胰胆管亚型中更为常见（p=0.018），并与更高的组织学分级相关（p=0.008）。人表皮生长因子受体2与临床病理特征无相关性，而c-Met在淋巴结阴性组中更常见（p=0.004），且常与表皮生长因子受体共表达（p=0.049）。表皮生长因子受体阳性患者的无病生存期（风险比=2.89；95%置信区间，1.35–6.20；p=0.061）和总生存期（风险比=6.89；95%置信区间，2.94–16.2；p=0.026）均较表皮生长因子受体阴性患者更差。人表皮生长因子受体2阳性壶腹腺癌患者的生存期有缩短趋势，但无统计学意义，而c-Met对生存结局无影响。在全身性疾病背景下，生存结局未因表皮生长因子受体、人表皮生长因子受体2和c-Met的表达差异而改变，但人表皮生长因子受体2阳性组显示出无进展生存期较差的趋势（风险比=1.90；95%置信区间，0.56–6.41；p=0.166）。本研究强调了表皮生长因子受体、人表皮生长因子受体2和c-Met作为壶腹腺癌个体化治疗靶点的潜力，值得进一步研究以评估靶向治疗的效果。

原文链接：

Prognostic Significance of EGFR, HER2, and c-Met Overexpression in Surgically Treated Patients with Adenocarcinoma of the Ampulla of Vater